Changes of Serum Complement C1q in Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2022.02.030
- Author:
Cheng-Si GUI
1
;
Shang-Qin LIU
2
Author Information
1. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China.
2. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China,E-mail: ubeliu@aliyun.com.
- Publication Type:Journal Article
- Keywords:
complement C1q;
immunodeficiency;
multiple myeloma;
tumor burden
- MeSH:
Albumins;
Bone Marrow;
Complement C1q;
Humans;
Multiple Myeloma;
Risk Factors
- From:
Journal of Experimental Hematology
2022;30(2):506-510
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the change of serum C1q in the course of multiple myeloma (MM) and its correlation with clinical characteristics.
METHODS:A total of 138 newly diagnosed MM patients in Zhongnan Hospital of Wuhan University from June 2016 to December 2019 were selected as research objects, during the same period 50 age-matched anemia patients, 50 lymphoma patients, 50 leukemia patients, and 50 myelodysplastic syndrome (MDS) patients were selected as control groups. All the patients met WHO disease classification, and were definitely diagnosed by pathology or bone marrow smear/biopsy. The changes of C1q between MM patients and control group, as well as in different therapeutic responses of MM patients before and after treatment were compared, also the difference of clinical characteristics among MM patients with different C1q level, so as to analyze risk factors which led to C1q decline.
RESULTS:The average value of C1q in MM patients was (128.18±51.24) mg/L, which was significantly lower than control group (P<0.01). The levels of white blood cell, platelet (PLT), hemoglobin (Hb), serum calcium, albumin, lactate dehydrogenase (LDH) in newly diagnosed high C1q group were significantly higher than those in low C1q group (P<0.05). Logistic analysis showed that the levels of PLT, Hb, albumin, and LDH in newly diagnosed high C1q group were higher than those in low C1q group (r=0.248, r=0.394, r=0.405, r=0.295). After treatment, the levels of C1q in MM patients with complete remission and very good partial remission were significantly higher than before treatment (P<0.05), while those with partial remission and stable disease also increased but not significantly (P>0.05).
CONCLUSION:The C1q level in MM patients is significantly lower than that in patients with other hematologic system diseases, and it increases with the remission of the disease after treatment.
